CN115461328B - 用于制备激酶抑制剂的方法 - Google Patents

用于制备激酶抑制剂的方法

Info

Publication number
CN115461328B
CN115461328B CN202180031136.7A CN202180031136A CN115461328B CN 115461328 B CN115461328 B CN 115461328B CN 202180031136 A CN202180031136 A CN 202180031136A CN 115461328 B CN115461328 B CN 115461328B
Authority
CN
China
Prior art keywords
compound
group
solvent
reaction mixture
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180031136.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN115461328A (zh
Inventor
F·德莫林
K·薛华
S·沙克雅
王勇
许维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Priority to CN202511511945.4A priority Critical patent/CN121591655A/zh
Publication of CN115461328A publication Critical patent/CN115461328A/zh
Application granted granted Critical
Publication of CN115461328B publication Critical patent/CN115461328B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180031136.7A 2020-04-30 2021-04-30 用于制备激酶抑制剂的方法 Active CN115461328B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511511945.4A CN121591655A (zh) 2020-04-30 2021-04-30 用于制备激酶抑制剂的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063017739P 2020-04-30 2020-04-30
US63/017,739 2020-04-30
PCT/US2021/030035 WO2021222673A1 (en) 2020-04-30 2021-04-30 Processes for the preparation of a kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511511945.4A Division CN121591655A (zh) 2020-04-30 2021-04-30 用于制备激酶抑制剂的方法

Publications (2)

Publication Number Publication Date
CN115461328A CN115461328A (zh) 2022-12-09
CN115461328B true CN115461328B (zh) 2025-11-07

Family

ID=76076455

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180031136.7A Active CN115461328B (zh) 2020-04-30 2021-04-30 用于制备激酶抑制剂的方法
CN202511511945.4A Pending CN121591655A (zh) 2020-04-30 2021-04-30 用于制备激酶抑制剂的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511511945.4A Pending CN121591655A (zh) 2020-04-30 2021-04-30 用于制备激酶抑制剂的方法

Country Status (18)

Country Link
US (1) US12497367B2 (https=)
EP (1) EP4143169B1 (https=)
JP (2) JP7728795B2 (https=)
KR (1) KR20230005190A (https=)
CN (2) CN115461328B (https=)
AU (1) AU2021263474A1 (https=)
BR (1) BR112022021712A2 (https=)
CA (1) CA3176042A1 (https=)
CL (1) CL2022003008A1 (https=)
CO (1) CO2022015205A2 (https=)
CR (1) CR20220551A (https=)
GE (1) GEP20267875B (https=)
IL (2) IL297684B1 (https=)
MX (1) MX2022013528A (https=)
PE (1) PE20230110A1 (https=)
PH (1) PH12022552821A1 (https=)
TW (1) TWI887405B (https=)
WO (1) WO2021222673A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117402114A (zh) * 2018-01-26 2024-01-16 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
TW202334090A (zh) * 2021-11-03 2023-09-01 美商艾克塞里克斯公司 用於治療激酶依賴性病症之化合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1154105A (zh) * 1994-06-08 1997-07-09 H·隆德贝克有限公司 4-芳基-1-(二氢化茚甲基、二氢苯并呋喃甲基或二氢苯并噻吩甲基)哌啶、-四氢吡啶或哌嗪类化合物
CN101466672A (zh) * 2006-06-12 2009-06-24 诺瓦提斯公司 N-羟基-3-[4-[[[2-(2-甲基-1h-吲哚-3-基)乙基]氨基]甲基]苯基]-2e-2-丙烯酰胺的盐
CN103221035A (zh) * 2010-07-16 2013-07-24 埃克塞里艾克西斯公司 C-met调节剂药物组合物
WO2019148044A1 (en) * 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CN113329790A (zh) * 2018-12-13 2021-08-31 埃克塞里艾克西斯公司 激酶抑制剂的结晶形式和盐形式

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA954689B (en) 1994-06-08 1996-01-29 Lundbeck & Co As H 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines
NZ572547A (en) 2006-06-12 2011-06-30 Novartis Ag SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-yl)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE
JP5486606B2 (ja) * 2008-11-13 2014-05-07 エクセリクシス， インク． キノリン誘導体の調製方法
NZ779754A (en) * 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
CN104395284A (zh) 2011-10-20 2015-03-04 埃克塞里艾克西斯公司 制备喹啉衍生物的方法
EP3174854B1 (en) 2014-07-31 2022-08-24 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
CR20250117A (es) 2018-01-26 2025-05-09 Exelixis Inc COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-0355)
CA3088198A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CN109761899B (zh) 2019-02-14 2022-11-15 广州六顺生物科技股份有限公司 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1154105A (zh) * 1994-06-08 1997-07-09 H·隆德贝克有限公司 4-芳基-1-(二氢化茚甲基、二氢苯并呋喃甲基或二氢苯并噻吩甲基)哌啶、-四氢吡啶或哌嗪类化合物
CN101466672A (zh) * 2006-06-12 2009-06-24 诺瓦提斯公司 N-羟基-3-[4-[[[2-(2-甲基-1h-吲哚-3-基)乙基]氨基]甲基]苯基]-2e-2-丙烯酰胺的盐
CN103221035A (zh) * 2010-07-16 2013-07-24 埃克塞里艾克西斯公司 C-met调节剂药物组合物
WO2019148044A1 (en) * 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CN113329790A (zh) * 2018-12-13 2021-08-31 埃克塞里艾克西斯公司 激酶抑制剂的结晶形式和盐形式

Also Published As

Publication number Publication date
CN115461328A (zh) 2022-12-09
GEP20267875B (en) 2026-03-25
EP4143169B1 (en) 2026-04-15
JP2025128388A (ja) 2025-09-02
CL2022003008A1 (es) 2023-06-23
TW202208335A (zh) 2022-03-01
MX2022013528A (es) 2022-11-16
PH12022552821A1 (en) 2024-02-12
CR20220551A (es) 2022-12-07
CN121591655A (zh) 2026-03-03
US20230192619A1 (en) 2023-06-22
IL297684B1 (en) 2026-03-01
EP4143169A1 (en) 2023-03-08
CO2022015205A2 (es) 2022-10-31
PE20230110A1 (es) 2023-01-25
IL297684A (en) 2022-12-01
BR112022021712A2 (pt) 2022-12-06
IL324105A (en) 2025-12-01
AU2021263474A1 (en) 2022-11-17
US12497367B2 (en) 2025-12-16
JP2023524692A (ja) 2023-06-13
WO2021222673A1 (en) 2021-11-04
JP7728795B2 (ja) 2025-08-25
TWI887405B (zh) 2025-06-21
CA3176042A1 (en) 2021-11-04
KR20230005190A (ko) 2023-01-09

Similar Documents

Publication Publication Date Title
RU2742234C1 (ru) Кумариноподобное циклическое соединение в качестве ингибитора мек и его применение
JP2025128388A (ja) キナーゼ阻害剤を調製するためのプロセス
JP6947749B2 (ja) チロシンキナーゼ阻害剤及びその誘導体を製造する方法
BRPI0615314A2 (pt) métodos de preparação de benzimidazóis substituìdos
CA2838194A1 (en) Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
JP2008517942A (ja) Ｃ−ｆｍｓキナーゼの阻害剤
JP2024505254A (ja) Ｍｋ２阻害剤、その合成、及びその中間体
CN102796079B (zh) 一种甲磺酸氟马替尼的制备方法
RS60118B1 (sr) Postupak za pripremu 1-(4-(4-(3,4-dihloro-2-fluorofenilamino)-7-metoksikvinazolin-6-iloksi)piperidin-1-il)-prop-2-en-1-on hidrohlorida i intermedijeri koji se u njemu koriste
CN105330653A (zh) 喹唑啉衍生物
KR20070036025A (ko) 치환된 트리아졸 화합물의 제조방법
KR100923540B1 (ko) 5-아실하이드라진카르보닐-3,4-디치환 피라졸 유도체 및이의 제조방법
ES2303758B1 (es) Nuevos derivados de piridin-3-amina.
CA2395407C (en) Method for producing 4-(heteroaryl-methyl)-1(2h)-phthalazinones
EA052237B1 (ru) Способы получения ингибитора киназы
CN111943853B (zh) 一种培唑帕尼杂质的制备方法
CN117658986A (zh) Ar拮抗剂trc-253的制备方法
KR100832659B1 (ko) 에스-(+)-프라니디핀 및 그 제조방법
JP2024537339A (ja) ベンゾフラン誘導体の調製方法
CA3214107A1 (en) New process for the synthesis of 5-{5-chloro-2-[(3s)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h)- carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds
CN114014847A (zh) 一种含苯并噻吩嘧啶衍生物及其制备方法和在制备抗肿瘤药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant